Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
Jane S Myung, Grant D Aaker, Szilárd KissDepartment of Ophthalmology, Weill Cornell Medical Center, New York, NY, USAPurpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA) in noninfectious po...
Guardado en:
Autores principales: | Jane S Myung, Grant D Aaker, Szilárd Kiss |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/66ac5f88b0294b73b3f0fec029240d0b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
por: Hunter RS, et al.
Publicado: (2011) -
Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion
por: Ryder SJ, et al.
Publicado: (2015) -
Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard Jr JD, et al.
Publicado: (2012) -
Management of noninfectious posterior uveitis with intravitreal drug therapy
por: Tan HY, et al.
Publicado: (2016) -
Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis
por: Tufail A, et al.
Publicado: (2018)